Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Long-term Imatinib Recommended for Metastatic GIST Even After Complete Resection, French Study Shows

July 1, 2006
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 15 No 7
Volume 15
Issue 7

Patients with metastatic gastrointestinal stromal tumors (GIST) who are in complete remission after surgical resection remain at high risk for relapse and should continue long-term treatment with imatinib (Gleevec), according to Binh Nguyen Bui, MD, of Institut Bergonie, Bordeaux, France. Dr. Bui reported results of the French Sarcoma Group BFR14 randomized phase III trial at the American Society of Clinical Oncology 42nd Annual Meeting (abstract 9501).

ATLANTA-Patients with metastatic gastrointestinal stromal tumors (GIST) who are in complete remission after surgical resection remain at high risk for relapse and should continue long-term treatment with imatinib (Gleevec), according to Binh Nguyen Bui, MD, of Institut Bergonie, Bordeaux, France. Dr. Bui reported results of the French Sarcoma Group BFR14 randomized phase III trial at the American Society of Clinical Oncology 42nd Annual Meeting (abstract 9501).

Although this trial was described as a study of adjuvant imatinib, session chair George D. Demetri, MD, of Harvard Medical School and Dana-Farber Cancer Institute, pointed out that it was more a study of the benefits of surgery as an adjuvant to imatinib treatment.

The study, supported by Novartis, enrolled 290 patients with metastatic disease; patients had surgery if there was thought to be a possibility of complete resection (R0-R1). All patients were treated with imatinib (400 mg/d), and 239 patients (either complete response to imatinib or R0-R1 resection) were randomized to continuation of imatinib (400 mg/d) until disease progression or discontinuation of imatinib.

Dr. Bui reported 3-year follow-up data for 153 patients, including 99 with initial R0, R1, or Rx (indeterminate) surgery of metastases (surgery group) and 54 without initial surgery or with R2 surgery of metastases (the nonsurgery group). Primary disease was gastric in about 40% of each group. However, only 8 patients (15.4%) in the no-surgery group had small bowel primary disease, compared with 40 (41.2%) in the surgery group.

According to Dr. Bui, the 3-year data show no difference in overall survival between the patients with complete resection and those with residual tumor. There was also no overall survival difference between the nonsurgery patients and those who had R0-R1 resections.

Among the 40% of patients who progressed, Dr. Bui said, there was no difference in progression-free interval between the surgery and nonsurgery groups.

"Subgroup analysis [for overall survival] found that patients with only liver metastases may have some marginal benefit from complete resection before imatinib treatment (P = .056)," Dr. Bui said. In addition, among the gastric primary GIST patients, overall survival was higher in the surgery group, compared with the no-surgery group (P = .044). Dr. Bui noted that the numbers were small in both of these subgroup analyses.

The researchers concluded that these results "justify imatinib treatment of initially resected metastatic GIST as in other metastatic diseases." Dr. Bui noted that optimal duration of imatinib has yet to be determined.

Articles in this issue

Surgeons Perform Remote Robotic Animal Nephrectomy Over Public Internet: A First
High-Quality Screening Colonoscopy Priority for GI Docs
Genentech Seeks Expanded Use of Avastin in Breast Cancer
Denosumab Suppresses Bone Resorption in Breast Ca Mets
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)
FDA Approves Revlimid for Myeloma Rx
Real-Time RT Planning, Delivery in the Bronx
Phase III Trial of Enzastaurin for NHL Patients Initiated
Dr. Niederhuber, New Acting Director of NCI, Confronts the Old Problem of an Ever-Declining Institute Budget
Racial Disparities in Prostate Ca Recurrence
HNPCC Pts May Reject Prophylactic Subtotal Colectomy
Improved Colonoscopy Techniques Increase Patient Comfort
New Agents Top Standard Rx in First-Line Advanced RCC
Two Cancer Bills Introduced in the US House of Representatives
Interventions Increase Chemotherapy Center Capacity
Recent Videos
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Future work may focus on optimizing symptom management associated with percutaneous transesophageal gastrostomy placement in malignant bowel obstructions.
Post-operative length of stay ranged from 4 to 9 days for patients who underwent percutaneous transesophageal gastrostomy for malignant bowel obstructions.
Treatment with KRAS inhibitors may help mitigate a common driver of genetic alteration across a majority of pancreatic cancers.
Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
Updated results from the BREAKWATER study seemed to be most impactful to the CRC space, according to Michael J. Pishvaian, MD, PhD.
Related Content
Advertisement

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Jason M. Broderick
May 31st 2025
Article

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

Gina Mauro
May 31st 2025
Article

Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.


T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

Tim Cortese
May 31st 2025
Article

T-DXd improved OS, PFS, ORR, and DOR vs ramucirumab plus paclitaxel in the second-line treatment of HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

Related Content
Advertisement

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Novel Therapy Yields Anti-Tumor Activity in KRAS G12C–Mutated CRC

Jason M. Broderick
May 31st 2025
Article

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.


The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.


Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Nivolumab/Ipilimumab Sustain Benefit Vs Chemo or Nivolumab in MSI-H/dMMR CRC

Jordyn Sava
May 31st 2025
Article

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.


Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

Educating Patients and Clinicians on End-of-Life Care and Discussions

Kelley A. Rone, DNP, RN, AGNP-c
November 11th 2024
Podcast

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.


ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

ctDNA-Informed Treatment Doesn’t Impact RFS in Stage III Colon Cancer

Gina Mauro
May 31st 2025
Article

Escalated adjuvant chemotherapy did not improve recurrence-free survival in patients with stage III colon cancer when using a ctDNA-informed approach.


T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

Tim Cortese
May 31st 2025
Article

T-DXd improved OS, PFS, ORR, and DOR vs ramucirumab plus paclitaxel in the second-line treatment of HER2-positive gastric cancer or gastroesophageal junction adenocarcinoma.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.